Boston Scientific Co. (NYSE:BSX) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC increased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 14.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,271 shares of the medical equipment provider's stock after buying an additional 3,879 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Boston Scientific were worth $2,704,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in Boston Scientific in the 4th quarter worth approximately $190,780,000. State Street Corp grew its stake in shares of Boston Scientific by 2.3% during the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after purchasing an additional 1,389,172 shares during the period. Fisher Funds Management LTD acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $94,710,000. Fisher Asset Management LLC grew its stake in shares of Boston Scientific by 21.6% during the 4th quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock worth $518,138,000 after purchasing an additional 1,028,977 shares during the period. Finally, Impax Asset Management Group plc grew its stake in shares of Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider's stock worth $457,138,000 after purchasing an additional 815,403 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Truist Financial raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. Morgan Stanley lifted their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.91.

Boston Scientific Trading Down 0.6 %

Shares of NYSE BSX traded down $0.57 during trading on Tuesday, hitting $98.33. 1,026,763 shares of the company were exchanged, compared to its average volume of 5,726,030. Boston Scientific Co. has a 12-month low of $66.16 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a fifty day moving average price of $101.21 and a 200-day moving average price of $91.97. The firm has a market capitalization of $145.12 billion, a PE ratio of 78.81, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.